Fred Hutch, Seattle Cancer Care Alliance, and UW Medicine Complete Restructure of Partnership

Learn More


Novel Treatment for Neuropathies and Neurodegeneration

Use of IL-17c as a novel neurotrophic factor can be applied to treat neurodegenerative disorders.

  • Stage: Preclinical in vitro
  • Type: Therapeutic
  • Categories: Protein / Peptide

Technology Overview

Dr. Corey and his colleagues have discovered that Interleukin-17c, previously only known as a cytokine, is secreted by keratinocytes during HSV infection and acts as a neurotrophic factor for neural cells. They demonstrated for the first time, that IL-17c can promote neural cell survival, neural growth, and axon guidance. Use of IL-17c as a novel neurotrophic factor can be applied to treat neurodegenerative disorders, for example, neuropathies in the peripheral nervous system that cause weakness, paralysis, numbness or pain. Treatment using IL-17c can be applied to a vast array of patients experiencing neuropathies including those caused by diabetes, autoimmune disorders, tumors, heredity, infections, chemotherapy, medications, toxins, and trauma.


  • Neurodegenerative disorders
  • Peripheral neuropathies
  • Neuropathic pain
  • Diabetic patients


  • Promote neural cell survival
  • Neural growth
  • Axon guidance

Patent Information

WO 2017007960

Market Overview

Peripheral neuropathies affect 20 million people in the U.S. Approximately 30% of peripheral neuropathies are caused by diabetes. Neuropathic pain market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan was $6.3 billion in 2012.

Investigator Overview

Larry Corey, PhD, Vaccine and Infectious Disease Division
Tech ID: 15-020
Asset 1